IGC Pharma Maintains Compliance as Non-Accelerated Filer
Ticker: IGC · Form: 10-K · Filed: Jun 27, 2025 · CIK: 1326205
| Field | Detail |
|---|---|
| Company | Igc Pharma, Inc. (IGC) |
| Form Type | 10-K |
| Filed Date | Jun 27, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: Pharmaceuticals, 10-K Filing, Non-Accelerated Filer, SEC Compliance, Small Cap Pharma, Maryland Company, NYSE American
Related Tickers: IGC
TL;DR
**IGC Pharma's small size and non-accelerated filer status signal higher risk and slower information flow for investors, making it a speculative play.**
AI Summary
IGC Pharma, Inc. reported its fiscal year ended March 31, 2025, operating as a non-accelerated filer. The company, trading under the ticker IGC on the NYSE American LLC, has maintained its compliance with SEC filing requirements, having filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months. IGC Pharma, Inc. is incorporated in Maryland with its principal executive offices located at 10224 Falls Road, Potomac, Maryland 20854. The company's business phone number is 301-983-0998. The filing indicates a consistent operational status without immediate major shifts in its reporting classification, suggesting a stable, albeit smaller, market presence. Specific revenue and net income figures are not provided in the excerpt, preventing a detailed financial performance summary.
Why It Matters
IGC Pharma's status as a non-accelerated filer indicates it has a public float of less than $75 million, which often means less liquidity and higher volatility for investors compared to larger companies. This classification also means it has more time to file its annual and quarterly reports, potentially delaying critical information for investors. For employees, this status suggests a smaller operational scale, while customers might see a more niche or specialized product focus. In the broader market, IGC Pharma operates in the pharmaceutical preparations sector, a highly competitive industry where larger players like Pfizer or Johnson & Johnson dominate, making IGC's growth trajectory more challenging.
Risk Assessment
Risk Level: medium — The company's classification as a 'non-accelerated filer' indicates a public float of less than $75 million, which inherently suggests higher investment risk due to potentially lower liquidity and market capitalization. Furthermore, the pharmaceutical preparations industry (SIC 2834) is highly competitive and capital-intensive, posing significant challenges for smaller entities like IGC Pharma to achieve substantial growth and profitability.
Analyst Insight
Investors should approach IGC Pharma with caution, recognizing its smaller market capitalization and the inherent risks of a non-accelerated filer in the competitive pharmaceutical sector. Conduct thorough due diligence on its specific drug pipeline and financial health, as the provided excerpt lacks detailed financial performance metrics.
Key Numbers
- $75M — Public Float Threshold (Defines 'non-accelerated filer' status, indicating IGC Pharma is below this threshold.)
- 20250331 — Fiscal Year End (The period covered by this 10-K filing.)
- 001-32830 — SEC File Number (Unique identifier for IGC Pharma's SEC filings.)
- 2834 — SIC Code (Standard Industrial Classification for 'Pharmaceutical Preparations', indicating IGC Pharma's industry.)
Key Players & Entities
- IGC Pharma, Inc. (company) — Registrant and filer of the 10-K
- NYSE American LLC (regulator) — Exchange where IGC Common Stock is registered
- Maryland (regulator) — State of incorporation for IGC Pharma, Inc.
- 001-32830 (regulator) — Commission file number for IGC Pharma, Inc.
- 0001326205 (company) — Central Index Key (CIK) for IGC Pharma, Inc.
- 20854 (dollar_amount) — Zip Code for IGC Pharma's business address
- 301-983-0998 (dollar_amount) — Business phone number for IGC Pharma
- March 31, 2025 (dollar_amount) — Fiscal year end date for the 10-K filing
- 10224 Falls Road, Potomac, Maryland (company) — Principal Executive Offices address for IGC Pharma
- 03 Life Sciences (company) — Organization Name associated with the EIN
FAQ
What is IGC Pharma, Inc.'s fiscal year end date?
IGC Pharma, Inc.'s fiscal year ended on March 31, 2025, as stated in their 10-K filing.
Where are IGC Pharma, Inc.'s principal executive offices located?
IGC Pharma, Inc.'s principal executive offices are located at 10224 Falls Road, Potomac, Maryland 20854.
Is IGC Pharma, Inc. a well-known seasoned issuer?
No, IGC Pharma, Inc. is not a well-known seasoned issuer, as indicated by the unchecked box in their 10-K filing.
What is IGC Pharma, Inc.'s trading symbol and on which exchange is it registered?
IGC Pharma, Inc.'s trading symbol is IGC, and its common stock is registered on the NYSE American LLC.
Has IGC Pharma, Inc. filed all required reports with the SEC?
Yes, IGC Pharma, Inc. has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months.
What is IGC Pharma, Inc.'s classification regarding accelerated filer status?
IGC Pharma, Inc. is classified as a non-accelerated filer, meaning its public float is less than $75 million.
What is the Standard Industrial Classification (SIC) for IGC Pharma, Inc.?
IGC Pharma, Inc.'s Standard Industrial Classification is 2834, which corresponds to 'Pharmaceutical Preparations'.
What is the business phone number for IGC Pharma, Inc.?
The business phone number for IGC Pharma, Inc. is 301-983-0998.
When was IGC Pharma, Inc. formerly known as India Globalization Capital, Inc.?
IGC Pharma, Inc. changed its name from India Globalization Capital, Inc. on May 5, 2005.
What is the significance of IGC Pharma being a non-accelerated filer for investors?
Being a non-accelerated filer means IGC Pharma has a public float under $75 million, which can imply lower liquidity and potentially higher investment risk compared to larger, more established companies.
Industry Context
IGC Pharma, Inc. operates within the Pharmaceutical Preparations industry (SIC Code 2834). This sector is characterized by significant research and development investment, stringent regulatory oversight from bodies like the FDA, and a competitive landscape driven by innovation and patent protection. Trends include a growing focus on specialized therapeutics, advancements in biotechnology, and evolving market access strategies.
Regulatory Implications
As a pharmaceutical company, IGC Pharma, Inc. is subject to extensive regulatory scrutiny regarding drug development, manufacturing, and marketing. Compliance with FDA regulations and other health authorities is critical. The company's status as a non-accelerated filer suggests it is a smaller entity, which may influence the scope of certain regulatory disclosures but does not exempt it from core industry compliance.
What Investors Should Do
- Review full 10-K for detailed financial statements.
- Analyze the 'Risk Factors' section of the 10-K.
- Monitor SEC filings for updates on product development and regulatory milestones.
Key Dates
- 2025-03-31: Fiscal Year End — Marks the end of the reporting period for the 10-K filing.
- 2025-06-27: 10-K Filing Date — Indicates the date the annual report was officially submitted to the SEC.
Glossary
- Non-accelerated filer
- A type of filer that meets certain criteria, including having a public float of less than $75 million, and is not required to comply with certain accelerated filing requirements. (IGC Pharma, Inc. is classified as a non-accelerated filer, indicating its market capitalization and public float are below specific thresholds.)
- SIC Code 2834
- Standard Industrial Classification code for 'Pharmaceutical Preparations', which categorizes companies involved in the manufacturing of drugs and medicines. (This code confirms IGC Pharma, Inc.'s primary industry focus is in the pharmaceutical sector.)
- Form 10-K
- An annual report required by the U.S. Securities and Exchange Commission (SEC), which gives a comprehensive summary of a company's financial performance. (This document provides detailed financial and operational information for IGC Pharma, Inc. for the fiscal year ended March 31, 2025.)
- NYSE American LLC
- A stock exchange operated by NYSE Group, Inc., a subsidiary of Intercontinental Exchange. It lists smaller companies compared to the New York Stock Exchange. (IGC Pharma, Inc.'s common stock is traded on this exchange under the ticker symbol IGC.)
Year-Over-Year Comparison
Information comparing the current 10-K filing for the fiscal year ended March 31, 2025, to the previous year's filing is not available in the provided excerpt. Key metrics such as revenue growth, margin changes, and the emergence of new risks cannot be assessed without access to the prior year's financial data and disclosures.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on June 27, 2025 regarding IGC Pharma, Inc. (IGC).